A patient infected with SARS-Cov-2 presents with DIHS syndrome induced by olanzapine: diagnostic difficulties

IF 0.2 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Postȩpy higieny i medycyny doświadczalnej Pub Date : 2023-01-01 DOI:10.2478/ahem-2023-0016
Michalina Pinkosz, Mateusz Szymański, Monika Cendrowska-Pinkosz
{"title":"A patient infected with SARS-Cov-2 presents with DIHS syndrome induced by olanzapine: diagnostic difficulties","authors":"Michalina Pinkosz, Mateusz Szymański, Monika Cendrowska-Pinkosz","doi":"10.2478/ahem-2023-0016","DOIUrl":null,"url":null,"abstract":"Abstract Drug-induced hypersensitivity syndrome (DIHS) is a potentially life-threatening reaction. The pathology of DIHS has been connected with adverse reactions to drugs; however, it has been observed that viruses and other infectious factors may induce similar responses in the body. COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently become a major challenge for worldwide healthcare. The dermatological symptoms occur in approximately 5.95% of COVID-19 patients, however, they are not exclusively a manifestation of SARS-CoV-2 infection. Certain skin-related symptoms might result from therapeutic drug administration, personal protective equipment, or sanitizers used by medical personnel. The complex pathomechanism of those symptoms leads to multiple diagnostic difficulties. This article describes a case of a 40-year-old man who was admitted to the intensive care unit (ICU) due to heavy respiratory failure in the course of SARS-CoV-2 infection. The patient has been treated with olanzapine for anxiety disorder for approximately 4 years. On the seventh day of treatment, the patient presented with a maculopapular rash, fever, and swollen upper lip. Because of these presented symptoms, the patient has been diagnosed with drug-induced hypersensitivity syndrome (DIHS). The results of blood analysis showed elevated levels of acute phase markers, liver and kidney damage markers, which are present both during COVID-19 and DIHS. Furthermore, the patient presented with peripheral eosinophilia, which is a distinctive feature of DIHS. In the course of COVID-19, the laboratory-measured levels of eosinophilic granulocytes declined to 0. Therefore, in the active phase of SARS-CoV-2 infection, the eosinophilia connected with DIHS was difficult to assess. In this paper, we compare and contrast the clinical and laboratory symptoms of COVID-19 and DIHS syndrome, describe patient's case and explain the diagnostics difficulties resulting from the concomitance of those disease entities.","PeriodicalId":20347,"journal":{"name":"Postȩpy higieny i medycyny doświadczalnej","volume":"20 1","pages":"0"},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postȩpy higieny i medycyny doświadczalnej","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/ahem-2023-0016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Drug-induced hypersensitivity syndrome (DIHS) is a potentially life-threatening reaction. The pathology of DIHS has been connected with adverse reactions to drugs; however, it has been observed that viruses and other infectious factors may induce similar responses in the body. COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently become a major challenge for worldwide healthcare. The dermatological symptoms occur in approximately 5.95% of COVID-19 patients, however, they are not exclusively a manifestation of SARS-CoV-2 infection. Certain skin-related symptoms might result from therapeutic drug administration, personal protective equipment, or sanitizers used by medical personnel. The complex pathomechanism of those symptoms leads to multiple diagnostic difficulties. This article describes a case of a 40-year-old man who was admitted to the intensive care unit (ICU) due to heavy respiratory failure in the course of SARS-CoV-2 infection. The patient has been treated with olanzapine for anxiety disorder for approximately 4 years. On the seventh day of treatment, the patient presented with a maculopapular rash, fever, and swollen upper lip. Because of these presented symptoms, the patient has been diagnosed with drug-induced hypersensitivity syndrome (DIHS). The results of blood analysis showed elevated levels of acute phase markers, liver and kidney damage markers, which are present both during COVID-19 and DIHS. Furthermore, the patient presented with peripheral eosinophilia, which is a distinctive feature of DIHS. In the course of COVID-19, the laboratory-measured levels of eosinophilic granulocytes declined to 0. Therefore, in the active phase of SARS-CoV-2 infection, the eosinophilia connected with DIHS was difficult to assess. In this paper, we compare and contrast the clinical and laboratory symptoms of COVID-19 and DIHS syndrome, describe patient's case and explain the diagnostics difficulties resulting from the concomitance of those disease entities.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1例SARS-Cov-2感染患者出现奥氮平诱导的DIHS综合征:诊断困难
药物致过敏综合征(DIHS)是一种潜在的危及生命的反应。DIHS的病理与药物不良反应有关;然而,已经观察到病毒和其他感染因素可能在体内引起类似的反应。由严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)引起的COVID-19最近已成为全球卫生保健的重大挑战。大约5.95%的COVID-19患者出现皮肤症状,然而,它们并不完全是SARS-CoV-2感染的表现。某些与皮肤有关的症状可能是由治疗药物的使用、个人防护设备或医务人员使用的消毒剂引起的。这些症状的复杂病理机制导致多重诊断困难。本文描述了一例40岁男性在SARS-CoV-2感染过程中因严重呼吸衰竭而入住重症监护病房(ICU)的病例。患者已接受奥氮平治疗焦虑症约4年。治疗第7天,患者出现黄斑丘疹、发热和上唇肿胀。由于这些症状,患者被诊断为药物致过敏综合征(DIHS)。血液分析结果显示,急性期标志物、肝脏和肾脏损伤标志物水平升高,这些标志物在COVID-19和DIHS期间都存在。此外,患者表现为外周嗜酸性粒细胞增多,这是DIHS的一个显著特征。在COVID-19过程中,实验室测量的嗜酸性粒细胞水平降至0。因此,在SARS-CoV-2感染的活跃期,与DIHS相关的嗜酸性粒细胞增多难以评估。本文对COVID-19和DIHS综合征的临床和实验室症状进行了比较和对比,对患者的病例进行了描述,并解释了这两种疾病并存导致的诊断困难。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Postȩpy higieny i medycyny doświadczalnej
Postȩpy higieny i medycyny doświadczalnej MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
0.60
自引率
0.00%
发文量
50
审稿时长
4-8 weeks
期刊介绍: Advances in Hygiene and Experimental Medicine (PHMD) is a scientific journal affiliated with the Institute of Immunology and Experimental Therapy by the Polish Academy of Sciences in Wrocław. The journal publishes articles from the field of experimental medicine and related sciences, with particular emphasis on immunology, oncology, cell biology, microbiology, and genetics. The journal publishes review and original works both in Polish and English. All journal publications are available via the Open Access formula in line with the principles of the Creative Commons licence.
期刊最新文献
Evaluation of selected psychological parameters: Perception of happiness and hope of success in patients with type 1 diabetes mellitus Anti-inflammatory activity of novel natural plant extracts composition—LevidorTM Liver complications of total parenteral nutrition: the latest therapeutic strategies Devices for the treatment of arterial hypertension Analgesic effects of oxycodone hydrochloride injection after laparoscopic cholecystectomy and influence on substance P, 5-hydroxytryptamine, and patient-controlled intravenous analgesia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1